Plus Therapeutics, Inc. (PSTV) Stock
PSTV Key Statistics
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
CEO: Marc H. Hedrick. Company website
PSTV — Frequently Asked Questions
What is the PSTV stock price today?
Plus Therapeutics, Inc. (PSTV) trades at $5.13, up 30.74% on the day, as of Nov 12, 2026 10:46 UTC.
What is Plus Therapeutics, Inc.'s market cap?
Plus Therapeutics, Inc. has a market capitalisation of $12.40M, calculated from the live PSTV share price and shares outstanding.
What is the P/E ratio of PSTV?
PSTV has no meaningful price-to-earnings ratio: Plus Therapeutics, Inc. lost $30,913.53 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Plus Therapeutics, Inc. make?
Plus Therapeutics, Inc. generated revenue of $5.21M over the trailing twelve months, which puts the stock at 2.38 times sales.
What is the 52-week range for PSTV?
PSTV has traded between $2.90 and $8.20 over the past 52 weeks, and the last price is 37.5% below that high.
Is Plus Therapeutics, Inc. profitable?
No. Plus Therapeutics, Inc. is loss-making, with a net margin of -429.43% over the trailing twelve months.
What is the analyst price target for PSTV?
Wall Street analysts rate PSTV Buy, with an average price target of $25.00, 387.8% above the current price.
What sector is Plus Therapeutics, Inc. in?
Plus Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Plus Therapeutics, Inc.?
Marc H. Hedrick is the chief executive of Plus Therapeutics, Inc., which employs 21 people.
Where can I track PSTV in real time?
QFI Terminal shows PSTV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PSTV live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PSTV in Terminal See plans